ASH News Daily 2017 - Issue 2 - C-5
VISIT US: BOOTH 2515
1-877-877-3536
MEDINFO@PCYC.COM
CHRONIC GRAFT VERSUS HOST
DISEASE ((cGVHD)-NEW ONSET,
MODERATE TO SEVERE
CLINICALTRIALS.GOV
KEY ELIGIBILITY CRITERIA
* Age ≥12 years old
* Karnofsky or Lansky (subjects <16 years) performance
score ≥60
* New onset moderate or severe cGVHD as defined by the 2014
NIH Consensus Development Project Criteria
A phase 3, randomized, double-blind study of ibrutinib
in combination with corticosteroids versus placebo in
combination with corticosteroids in subjects with
new-onset cGVHD
* May be receiving other immunosuppressants for the
prophylaxis or treatment of acute GVHD
* No previous systemic treatment for cGVHD
* Need for systemic treatment with corticosteroids for cGVHD
PCYC-1140-IM
(NCT02959944)
* Able to begin a prednisone dose ≥0.5 mg/kg/d for the
treatment of cGVHD
KEY ELIGIBILITY CRITERIA
* Histologically confirmed diagnosis of CD20-positive follicular
lymphoma (Grade 1, 2, or 3a) with Ann Arbor Stage II, III,
or IV disease
A phase 3, multicenter, randomized, double-blind, placebocontrolled study of ibrutinib in combination with rituximab
versus placebo in combination with rituximab in treatmentnaïve subjects with follicular lymphoma
* Measurable disease
* Age ≥70 years; or age 60-69 years who have one or
more comorbidities
* Meets one or more Groupe d'Etude des Lymphomes Folliculaires
(GELF) criteria
PCYC-1141-CA
(NCT02947347)
* ECOG performance status score of 0-2
* Adequate hematologic, hepatic, and renal function
* No previous treatment for follicular lymphoma
* No CNS lymphoma or leptomeningeal disease
MANTLE CELL LYMPHOMA
(MCL)-RELAPSED/REFRACTORY
KEY ELIGIBILITY CRITERIA
* Pathologically confirmed MCL with ≥1 measurable site
of disease
* At least 1, but no more than 5, prior treatment regimens for MCL
Phase 3 study of ibrutinib in combination
with venetoclax in subjects with MCL
PCYC-1143-CA
(NCT03112174)
* Subjects must have adequate fresh or paraffin
embedded tissue
* No history or evidence of central nervous system lymphoma
SYMPATICO
* No concurrent enrollment in another therapeutic investigational
study or prior therapy with ibrutinib or other BTK inhibitors
* No prior treatment with venetoclax or other BCL2 inhibitors
© Pharmacyclics LLC 2017
CMRC-02437 10/2017
FS:9.5"
F:10.5"
S:13.5"
FOLLICULAR LYMPHOMA-
TREATMENT NAÏVE
Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 2
ASH News Daily 2017 - Issue 2 - A-1
ASH News Daily 2017 - Issue 2 - A-2
ASH News Daily 2017 - Issue 2 - A-3
ASH News Daily 2017 - Issue 2 - A-4
ASH News Daily 2017 - Issue 2 - A-5
ASH News Daily 2017 - Issue 2 - A-6
ASH News Daily 2017 - Issue 2 - A-7
ASH News Daily 2017 - Issue 2 - A-8
ASH News Daily 2017 - Issue 2 - A-9
ASH News Daily 2017 - Issue 2 - A-10
ASH News Daily 2017 - Issue 2 - A-11
ASH News Daily 2017 - Issue 2 - A-12
ASH News Daily 2017 - Issue 2 - A-13
ASH News Daily 2017 - Issue 2 - A-14
ASH News Daily 2017 - Issue 2 - A-15
ASH News Daily 2017 - Issue 2 - A-16
ASH News Daily 2017 - Issue 2 - A-17
ASH News Daily 2017 - Issue 2 - A-18
ASH News Daily 2017 - Issue 2 - A-19
ASH News Daily 2017 - Issue 2 - A-20
ASH News Daily 2017 - Issue 2 - A-21
ASH News Daily 2017 - Issue 2 - A-22
ASH News Daily 2017 - Issue 2 - A-23
ASH News Daily 2017 - Issue 2 - A-24
ASH News Daily 2017 - Issue 2 - A-25
ASH News Daily 2017 - Issue 2 - A-26
ASH News Daily 2017 - Issue 2 - A-27
ASH News Daily 2017 - Issue 2 - A-28
ASH News Daily 2017 - Issue 2 - B-1
ASH News Daily 2017 - Issue 2 - B-2
ASH News Daily 2017 - Issue 2 - B-3
ASH News Daily 2017 - Issue 2 - B-4
ASH News Daily 2017 - Issue 2 - B-5
ASH News Daily 2017 - Issue 2 - B-6
ASH News Daily 2017 - Issue 2 - B-7
ASH News Daily 2017 - Issue 2 - B-8
ASH News Daily 2017 - Issue 2 - B-9
ASH News Daily 2017 - Issue 2 - B-10
ASH News Daily 2017 - Issue 2 - B-11
ASH News Daily 2017 - Issue 2 - B-12
ASH News Daily 2017 - Issue 2 - B-13
ASH News Daily 2017 - Issue 2 - B-14
ASH News Daily 2017 - Issue 2 - B-15
ASH News Daily 2017 - Issue 2 - B-16
ASH News Daily 2017 - Issue 2 - B-17
ASH News Daily 2017 - Issue 2 - B-18
ASH News Daily 2017 - Issue 2 - B-19
ASH News Daily 2017 - Issue 2 - B-20
ASH News Daily 2017 - Issue 2 - B-21
ASH News Daily 2017 - Issue 2 - B-22
ASH News Daily 2017 - Issue 2 - B-23
ASH News Daily 2017 - Issue 2 - B-24
ASH News Daily 2017 - Issue 2 - B-25
ASH News Daily 2017 - Issue 2 - B-26
ASH News Daily 2017 - Issue 2 - B-27
ASH News Daily 2017 - Issue 2 - B-28
ASH News Daily 2017 - Issue 2 - B-29
ASH News Daily 2017 - Issue 2 - B-30
ASH News Daily 2017 - Issue 2 - B-31
ASH News Daily 2017 - Issue 2 - B-32
ASH News Daily 2017 - Issue 2 - B-33
ASH News Daily 2017 - Issue 2 - B-34
ASH News Daily 2017 - Issue 2 - B-35
ASH News Daily 2017 - Issue 2 - B-36
ASH News Daily 2017 - Issue 2 - B-37
ASH News Daily 2017 - Issue 2 - B-38
ASH News Daily 2017 - Issue 2 - B-39
ASH News Daily 2017 - Issue 2 - B-40
ASH News Daily 2017 - Issue 2 - B-41
ASH News Daily 2017 - Issue 2 - B-42
ASH News Daily 2017 - Issue 2 - B-43
ASH News Daily 2017 - Issue 2 - B-44
ASH News Daily 2017 - Issue 2 - B-45
ASH News Daily 2017 - Issue 2 - B-46
ASH News Daily 2017 - Issue 2 - B-47
ASH News Daily 2017 - Issue 2 - B-48
ASH News Daily 2017 - Issue 2 - B-49
ASH News Daily 2017 - Issue 2 - B-50
ASH News Daily 2017 - Issue 2 - B-51
ASH News Daily 2017 - Issue 2 - B-52
ASH News Daily 2017 - Issue 2 - B-53
ASH News Daily 2017 - Issue 2 - B-54
ASH News Daily 2017 - Issue 2 - B-55
ASH News Daily 2017 - Issue 2 - B-56
ASH News Daily 2017 - Issue 2 - C-1
ASH News Daily 2017 - Issue 2 - C-2
ASH News Daily 2017 - Issue 2 - C-3
ASH News Daily 2017 - Issue 2 - C-4
ASH News Daily 2017 - Issue 2 - C-5
ASH News Daily 2017 - Issue 2 - C-6
ASH News Daily 2017 - Issue 2 - C-7
ASH News Daily 2017 - Issue 2 - C-8
ASH News Daily 2017 - Issue 2 - C-9
ASH News Daily 2017 - Issue 2 - C-10
ASH News Daily 2017 - Issue 2 - C-11
ASH News Daily 2017 - Issue 2 - C-12
ASH News Daily 2017 - Issue 2 - C-13
ASH News Daily 2017 - Issue 2 - C-14
ASH News Daily 2017 - Issue 2 - C-15
ASH News Daily 2017 - Issue 2 - C-16
ASH News Daily 2017 - Issue 2 - C-17
ASH News Daily 2017 - Issue 2 - C-18
ASH News Daily 2017 - Issue 2 - C-19
ASH News Daily 2017 - Issue 2 - C-20
ASH News Daily 2017 - Issue 2 - C-21
ASH News Daily 2017 - Issue 2 - C-22
ASH News Daily 2017 - Issue 2 - C-23
ASH News Daily 2017 - Issue 2 - C-24
ASH News Daily 2017 - Issue 2 - C-25
ASH News Daily 2017 - Issue 2 - C-26
ASH News Daily 2017 - Issue 2 - C-27
ASH News Daily 2017 - Issue 2 - C-28
ASH News Daily 2017 - Issue 2 - C-29
ASH News Daily 2017 - Issue 2 - C-30
ASH News Daily 2017 - Issue 2 - C-31
ASH News Daily 2017 - Issue 2 - C-32
https://www.nxtbookmedia.com